创新药再度活跃，港股通医疗ETF（520510）现涨近3.5%

Core Viewpoint - The recent interest rate cut expectations from the Federal Reserve have boosted market sentiment, particularly benefiting the healthcare sector in Hong Kong, as evidenced by the rise of the Hong Kong Stock Connect Medical ETF (520510) by nearly 3.5% [1] Group 1: Market Performance - The Hong Kong Stock Connect Medical ETF (520510) has seen significant gains, with leading holdings such as Innovent Biologics, Zai Lab, Kelun Pharmaceutical, and WuXi AppTec showing notable increases [1] - The ETF tracks a medical theme index that encompasses three major sub-sectors within the healthcare industry, with a weight of over 30% in CXO, over 20% in AI healthcare, and nearly 50% in innovative drugs [1] Group 2: Policy Developments - The National Healthcare Security Administration has released a plan for the adjustment of the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogs, which aims to establish a dual-track system of "Basic Medical Insurance + Commercial Insurance for Innovative Drugs" [1] - This new framework is designed to incorporate high-value innovative drugs into the commercial insurance catalog, alleviating pressure on the basic medical insurance fund while meeting diverse healthcare needs [1] Group 3: Industry Outlook - According to Industrial Securities, there has been some emotional fluctuation in the innovative drug and related industry chain recently; however, the overall fundamentals of the sector remain positive, with continued upward potential in valuations [1] - The anticipated catalysts for growth in the sector are expected to emerge, and the rising expectations of interest rate cuts in the U.S. are likely to have a positive impact on both the innovative drug and AI healthcare segments [1]